Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

BACKGROUND: Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Gastroenterol
Asıl Yazarlar: Braat, Arthur J. A. T., Kwekkeboom, Dik J., Kam, Boen L. R., Teunissen, Jaap J. M., de Herder, Wouter W., Dreijerink, Koen M. A., van Rooij, Rob, Krijger, Gerard C., de Jong, Hugo W. A. M., van den Bosch, Maurice A. A. J., Lam, Marnix G. E. H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Study Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6003090/
https://ncbi.nlm.nih.gov/pubmed/29902988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-018-0817-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller